Pentosan Polysulfate Sodium
drugOn this page
Also known as CartrophenElmironFibraseFibrezymHemoclarLysosanNSC-626201Pentosan polysulfate sodium saltPentosan polysulphate sodiumPentosane polysulfate sodiquePentosano polisulfato de sodioPZ-68PZ68Sodium pentosan polysulphateSp 54SP-54SP54ThrombocidPENTOSANE_POLYSULFATE
Summary
Pentosan Polysulfate Sodium (CHEMBL1201516) is an approved small molecule (ATC C05BA04); indicated across 7 conditions including varicose disease and interstitial cystitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C05BA04 (+1 more)
- Indications: 7 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201516 |
| Name | Pentosan Polysulfate Sodium |
| Type | Small molecule |
| Max phase | 4 |
| ATC | C05BA04, G04BX15 |
Also known as: Cartrophen, Elmiron, Fibrase, Fibrezym, Hemoclar, Lysosan, NSC-626201, Pentosan polysulfate sodium, Pentosan polysulfate sodium salt, Pentosan polysulphate sodium, Pentosane polysulfate sodique, Pentosano polisulfato de sodio
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| varicose disease | 4 | MONDO:0008638 | HP:0002619 |
| interstitial cystitis | 4 | MONDO:0018301 | EFO:0008507 |
| diarrheal disease | 3 | MONDO:0001673 | HP:0002014 |
| enteritis | 3 | MONDO:0043579 | MONDO:0043579 |
| osteoarthritis, knee | 3 | MONDO:0005416 | EFO:0004616 |
| prostatitis | 2 | MONDO:0005280 | EFO:0003830 |
| cystitis | 2 | MONDO:0006032 | EFO:1000025 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00003825 | PHASE3 | COMPLETED | Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy |
| NCT00236990 | PHASE2 | COMPLETED | An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland |
| NCT02930005 | PHASE2 | COMPLETED | Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders |
| NCT04814719 | Not specified | COMPLETED | Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).